European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
AuthorsBurnett, Alan K
Kell, W Jonathan
Milligan, Donald W
Yin, John A
Clark, Richard E
Hills, Robert K
AffiliationDepartment of Haematology, Cardiff University School of Medicine, Cardiff CF14 4XN, United Kingdom. firstname.lastname@example.org
MetadataShow full item record
AbstractPURPOSE: Treatment options for older patients with acute myeloid leukemia (AML) who are not considered suitable for intensive chemotherapy are limited. We assessed the second-generation purine nucleoside analog, clofarabine, in two similar phase II studies in this group of patients. PATIENTS AND METHODS: Two consecutive studies, UWCM-001 and BIOV-121, recruited untreated older patients with AML to receive up to four or six 5-day courses of clofarabine. Patients in UWCM-001 were either older than 70 years or 60 to 69 years of age with poor performance status (WHO > 2) or with cardiac comorbidity. Patients in BIOV-121 were >or= 65 years of age and deemed unsuitable for intensive chemotherapy. RESULTS: A total of 106 patients were treated in the two monotherapy studies. Median age was 71 years (range, 60 to 84 years), 30% had adverse-risk cytogenetics, and 36% had a WHO performance score >or= 2. Forty-eight percent had a complete response (32% complete remission, 16% complete remission with incomplete peripheral blood count recovery), and 18% died within 30 days. Interestingly, response and overall survival were not inferior in the adverse cytogenetic risk group. The safety profile of clofarabine in these elderly patients with AML who were unsuitable for intensive chemotherapy was manageable and typical of a cytotoxic agent in patients with acute leukemia. Patients had similar prognostic characteristics to matched patients treated with low-dose cytarabine in the United Kingdom AML14 trial, but had significantly superior response and overall survival. CONCLUSION: Clofarabine is active and generally well tolerated in this patient group. It is worthy of further evaluation in comparative trials and might be of particular use in patients with adverse cytogenetics.
CitationEuropean development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. 2010, 28 (14):2389-95 J Clin Oncol
JournalJournal of Clinical Oncology
- Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
- Authors: Tran H, Yang D
- Issue date: 2012 Jan
- Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
- Authors: Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K, Yin J, McMullin MF, Ali S, Bowen D, Hills RK, UK National Cancer Research Institute AML Working Group.
- Issue date: 2013 Aug 22
- Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
- Authors: Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM
- Issue date: 2012 Sep 15
- Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
- Authors: Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S
- Issue date: 2010 Feb 1
- Clofarabine in the treatment of elderly patients with acute myeloid leukemia.
- Authors: Aleem A, Anjum F, Algahtani F, Iqbal Z, Alsaleh K, Almomen A
- Issue date: 2013